Fig. 2From: The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patientsOverall survival according to CEA and CYFRA21-1 reduction ≥ 20%Back to article page